OneMedNet partners with Onco-Innovations’ Inka Health to provide U.S. oncology real-world data platform

Reuters04-01

<a href="https://laohu8.com/S/ONMD">OneMedNet</a> partners with Onco-Innovations’ Inka Health to provide U.S. oncology real-world data platform

OneMedNet entered collaboration with Inka Health, subsidiary of Onco-Innovations, to provide access to OneMedNet iRWD platform powered by Palantir Foundry.
Partnership targets faster oncology drug development for Onco-Innovations PNKP inhibitor program in PTEN/SHP1-deficient cancers.
Inka Health will use U.S. real-world oncology data from iRWD via selective pilot program following technical evaluation and qualification.
Initial work will support responder identification, potential indication expansion beyond advanced metastatic colorectal cancer, plus clinical and regulatory evidence generation.
Engagement also aims to improve SynoGraph, Inka Health causal-inference AI platform for predicting cancer treatment success and safety.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onemednet Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604010855PRIMZONEFULLFEED9682588) on April 01, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624516699?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 20:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624516699","market":"nz","top_or_hot":-1,"title":"OneMedNet partners with Onco-Innovations’ Inka Health to provide U.S. oncology real-world data platform","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ONMD\">OneMedNet</a> partners with Onco-Innovations’ Inka Health to provide U.S. oncology real-world data platform\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          OneMedNet entered collaboration with Inka Health, subsidiary of Onco-Innovations, to provide access to OneMedNet iRWD platform powered by <a href=\"https://laohu8.com/S/PLTR\">Palantir</a> Foundry.\n        </li>\n<li>\n          Partnership targets faster oncology drug development for Onco-Innovations PNKP inhibitor program in PTEN/SHP1-deficient cancers.\n        </li>\n<li>\n          Inka Health will use U.S. real-world oncology data from iRWD via selective pilot program following technical evaluation and qualification.\n        </li>\n<li>\n          Initial work will support responder identification, potential indication expansion beyond advanced metastatic colorectal cancer, plus clinical and regulatory evidence generation.\n        </li>\n<li>\n          Engagement also aims to improve SynoGraph, Inka Health causal-inference AI platform for predicting cancer treatment success and safety.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onemednet Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604010855PRIMZONEFULLFEED9682588) on April 01, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OneMedNet partners with Onco-Innovations’ Inka Health to provide U.S. oncology real-world data platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOneMedNet partners with Onco-Innovations’ Inka Health to provide U.S. oncology real-world data platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-01 20:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ONMD\">OneMedNet</a> partners with Onco-Innovations’ Inka Health to provide U.S. oncology real-world data platform\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          OneMedNet entered collaboration with Inka Health, subsidiary of Onco-Innovations, to provide access to OneMedNet iRWD platform powered by <a href=\"https://laohu8.com/S/PLTR\">Palantir</a> Foundry.\n        </li>\n<li>\n          Partnership targets faster oncology drug development for Onco-Innovations PNKP inhibitor program in PTEN/SHP1-deficient cancers.\n        </li>\n<li>\n          Inka Health will use U.S. real-world oncology data from iRWD via selective pilot program following technical evaluation and qualification.\n        </li>\n<li>\n          Initial work will support responder identification, potential indication expansion beyond advanced metastatic colorectal cancer, plus clinical and regulatory evidence generation.\n        </li>\n<li>\n          Engagement also aims to improve SynoGraph, Inka Health causal-inference AI platform for predicting cancer treatment success and safety.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onemednet Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604010855PRIMZONEFULLFEED9682588) on April 01, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BN0W2T93.GBP","symbol_name":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL1s1099:1","article_id":"2624516699","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624516699","pubTimestamp":1775048116,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"OneMedNet entered collaboration with Inka Health, subsidiary of Onco-Innovations, to provide access to OneMedNet iRWD platform powered by Palantir Foundry.Partnership targets faster oncology drug development for Onco-Innovations PNKP inhibitor program in PTEN/SHP1-deficient cancers.Inka Health will use U.S. real-world oncology data from iRWD via selective pilot program following technical evaluation and qualification.Initial work will support responder identification, potential indication expansion beyond advanced metastatic colorectal cancer, plus clinical and regulatory evidence generation.Engagement also aims to improve SynoGraph, Inka Health causal-inference AI platform for predicting cancer treatment success and safety.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BZ9MQY76.HKD":"FTGF CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (HKD) ACC","PLTU":"2倍做多PLTR ETF-Direxion","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","BK4613":"AI应用软件","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","PLTW":"PLTR周配息ETF-Roundhill","BK4547":"WSB热门概念","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","PTIR":"2倍做多PLTR ETF-GraniteShares","BK4167":"医疗保健技术","PLTY":"PLTR期权收益策略ETF-YieldMax","PLTZ":"2倍做空PLTR ETF-Defiance","BK4588":"碎股","PLOO":"2倍上限加速PLTR ETF-Leverage Shares","BK4112":"金融交易所和数据","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","ONNVF":"ONCO-INNOVATIONS LTD.","PLT":"Defiance Leveraged Long Plus Income PLTR ETF","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","PLTA":"ProShares Ultra PLTR ETF","PLYY":"GraniteShares YieldBOOST PLTR ETF","ONMD":"OneMedNet","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","PLTD":"1倍做空PLTR ETF-Direxion","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BK4023":"应用软件","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4543":"AI","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","PLTG":"2倍做多PLTR ETF-Leverage Shares","LU1861558580.USD":"日兴方舟颠覆性创新基金B","PLTI":"REX PLTR Growth & Income ETF","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","BK4585":"ETF&股票定投概念"},"translate_title":"OneMedNet与Onco-Innovations的Inka Health合作，提供美国肿瘤学真实世界数据平台","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLOO":0.6,"PLTU":0.6,"PLT":0.6,"PLTA":0.6,"PTIR":0.6,"ONNVF":1.89,"PLYY":0.6,"PLTY":0.6,"PLTD":0.6,"PLTI":0.6,"PLTW":0.6,"PLTZ":0.6,"ONMD":1.94,"PLTG":0.6},"content_text":"OneMedNet partners with Onco-Innovations’ Inka Health to provide U.S. oncology real-world data platform\n    \n\n\n          OneMedNet entered collaboration with Inka Health, subsidiary of Onco-Innovations, to provide access to OneMedNet iRWD platform powered by Palantir Foundry.\n        \n\n          Partnership targets faster oncology drug development for Onco-Innovations PNKP inhibitor program in PTEN/SHP1-deficient cancers.\n        \n\n          Inka Health will use U.S. real-world oncology data from iRWD via selective pilot program following technical evaluation and qualification.\n        \n\n          Initial work will support responder identification, potential indication expansion beyond advanced metastatic colorectal cancer, plus clinical and regulatory evidence generation.\n        \n\n          Engagement also aims to improve SynoGraph, Inka Health causal-inference AI platform for predicting cancer treatment success and safety.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onemednet Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604010855PRIMZONEFULLFEED9682588) on April 01, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624516699","isCrawlerRequest":true}